紫杉醇联合卡培他滨对晚期胃癌患者血清G-17、PGR、CA199水平及预后的影响分析  

Effect of paclitaxel combined with capecitabine on serum G-17,PGR,CA199 levels and prognosis in patients with advanced gastric cancer

作　　者：邢士超[1] 田炳如[2] 侯树峰[1] 赵静 鲁文权 XING Shichao;TIAN Bingru;HOU Shufeng(Department of Medical Oncology,Yuyao People's Hospital of Zhejiang Province,Yuyao 315400,China.)

机构地区：[1]余姚市人民医院肿瘤内科,浙江余姚315400 [2]余姚市人民医院检验科,浙江余姚315400

出　　处：《全科医学临床与教育》2023年第4期324-327,共4页Clinical Education of General Practice

摘　　要：目的分析紫杉醇联合卡培他滨对晚期胃癌患者血清胃泌素-17(G-17)、胃蛋白酶原比值(PGR)、糖类抗原199(CA199)水平及预后的影响。方法将80例晚期胃癌患者作为研究对象,随机分为对照组(n=40)和观察组(n=40),对照组给予多西他赛+顺铂+氟尿嘧啶治疗,观察组采用紫杉醇+卡培他滨治疗,比较两组临床疗效,治疗前后血清G-17、PGR、CA199水平,不良反应及预后等情况。结果观察组客观有效率(ORR)与对照组比较,差异无统计学意义(χ^(2)=0.46,P>0.05)。治疗前,两组血清G-17、PGR、CA199水平比较,差异均无统计学意义(t分别=0.51、0.13、0.73,P均>0.05);治疗后,观察组血清G-17、CA199水平均低于对照组(t分别=2.28、2.19,P均<0.05),PGR水平高于对照组(t=-2.03,P<0.05)。观察组恶心/呕吐、腹泻、白细胞减少、脱发发生率均低于对照组(χ^(2)分别=5.50、4.18、5.00、16.05,P均<0.05)。观察组治疗完成后1年累积生存率为50.00%,高于对照组的32.50%(χ^(2)=4.21,P<0.05)。结论紫杉醇联合卡培他滨可以更好地改善晚期胃癌患者血清G-17、PGR、CA199水平,减少不良反应,改善患者预后。Objective To analyze the effects of paclitaxel combined with capecitabine on serum gastrin(G-17),pep⁃sinogen ratio(PGR),carbohydrate antigen 199(CA199)and prognosis in patients with advanced gastric cancer.Meth⁃ods Totally 80 cases of patients with advanced gastric cancer were enrolled as the research object and randomized into control group(n=40)and observation group(n=40).The control group was given dorseyhe+cisplatin+fluorouracil ther⁃apy,the observation group was treated with paclitaxel+capecitabine.The clinical curative effect,serum G-17,PGR,CA199 levels,adverse reactions and prognosis before and after treatment between two groups were compared.Results The ORR between the two groups was not statistically different(χ^(2)=0.46,P>0.05).Before treatment,there was no statisti⁃cal difference in the G-17,PGR,and CA199 levels between two groups(t=0.51,0.13,0.73,P>0.05).After treatment,se⁃rum G-17 and CA199 levels in observation group were lower than those in control group(t=2.28,2.19,P<0.05),while the PGR level was higher than that in control group(t=-2.03,P<0.05).The incidences of nausea and vomiting,diar⁃rhea,leucopenia and alopecia in the observation group were lower than those in the control group(χ^(2)=5.50,4.18,5.00,16.05,P<0.05).The 1 year cumulative survival rate of the observation group after treatment was 50.00%,which was higher than 32.50%of the control group(χ^(2)=4.21,P<0.05).Conclusion Paclitaxel combined with capecitabine can im⁃prove the levels of serum G-17,PGR and CA199 in patients with advanced gastric cancer,prolong the survival time,re⁃duce adverse reactions.

关 键 词：晚期胃癌 紫杉醇 卡培他滨 胃泌素-17 胃蛋白酶原比值 糖类抗原199 预后 

分 类 号：R735.2[医药卫生—肿瘤]